LumaBridge
LumaBridge is a privately held, specialty clinical research organization (CRO) founded in 2014 in San Antonio, Texas. It provides tailored clinical trial guidance and personalized services to study sponsors, operating with a lean team of 51-100 employees.
- Company typePrivate
- Founded2014
- HeadquartersSan Antonio, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What LumaBridge does
LumaBridge is a specialty clinical research organization (CRO) founded in 2014 and headquartered in San Antonio, Texas. According to its own short positioning, the company provides "tailored clinical trial guidance and personalised services," indicating it competes in the niche segment of CROs that deliver customized study design, management, and execution support rather than high-volume commoditized clinical operations. The firm is privately held and for-profit, with a workforce of 51-100 employees, placing it firmly in the small/mid-market CRO tier.
Public information about LumaBridge's underlying technology stack, proprietary platforms, product portfolio, pricing structure, customer base, and partnership network is not available in the source material. The corporate website (lumabridge.com) renders only a verification/loading page at the time of capture, and no product listings, certifications, regulatory filings, or technology disclosures were extractable. Leadership consists of a Chief Operating Officer (Amanda Ferrier) and a Vice President and Head of Business Development (Todd Lehman), indicating a lean executive team focused on operational delivery and commercial growth.
The business model is service-based and consistent with conventional CRO economics: revenue is derived from fees for clinical trial services (study design, project management, monitoring, and related guidance), with no evidence of a SaaS, licensing, or marketplace revenue component. Given the lack of disclosed financials, funding history, customer logos, or geographic footprint data, the company's scale, growth profile, and competitive positioning cannot be precisely triangulated from public sources at this time.
LumaBridge firmographics
Firmographics- Name
- LumaBridge
- Website
- https://lumabridge.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- LumaBridge is a privately held, specialty clinical research organization (CRO) founded in 2014 in San Antonio, Texas. It provides tailored clinical trial guidance and personalized services to study sponsors, operating with a lean team of 51-100 employees.
- Ownership category
- akta.pro rank
LumaBridge industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Professional, Scientific, and Technical Services (54), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where LumaBridge is headquartered
LocationHeadquarters
- HQ city
- San Antonio
- HQ country
- United States
- HQ region
- North America
Markets served
LumaBridge business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
LumaBridge product offering
Product offeringCore offering
LumaBridge is a specialty clinical research organisation that provides tailored clinical trial guidance and personalised services to sponsor companies. It supports the planning and execution of clinical studies through customised engagement, operating as a boutique CRO rather than a large full-service provider.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Trial Guidance and Personalised Services Tailored clinical trial guidance and personalised study support delivered by a specialty clinical research organisation to sponsor clients in the pharmaceutical, biotechnology, and medical-device sectors.
Companies that use LumaBridge
Customer profileIdeal customer profiles1 record
LumaBridge technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LumaBridge partnerships and signals
Strategic signalRecent moves3 records
LumaBridge competitors and assessment
Company assessmentDirect peers
- Clinipace Worldwide: Mid-sized CRO focused on emerging and mid-sized biopharma sponsors with therapeutic-focused trial design and execution. Closely comparable scale and go-to-market profile.
- Synteract (now part of Citation Bio Group): Mid-market CRO serving emerging and mid-sized biopharma sponsors with therapeutic-focused trial services. Directly competes with LumaBridge for similar study awards.
- Worldwide Clinical Trials: Mid-market global CRO with strong therapeutic-area specialization (particularly neuroscience and rare disease). Directly comparable to LumaBridge as a specialty CRO competing for similar biotech sponsor work.
- Medpace Holdings: Mid-sized, therapeutically focused clinical CRO offering Phase I-IV trial services to biotech and pharma sponsors. Closely comparable to LumaBridge in operating model and target customer base, though substantially larger in scale.
- CTI Clinical Trial & Consulting Services: Specialty CRO with therapeutic-area expertise serving biotech and pharma sponsors. Comparable headcount, business model, and customer profile to LumaBridge.
- Premier Research: Specialty CRO focused on small-to-mid-sized biotech sponsors across niche therapeutic areas. Operates in the same competitive set as LumaBridge for outsourced clinical trial services.
Broad incumbents
- ICON plc: Global CRO offering Phase I-IV services across all major therapeutic areas post-PRA Health Sciences combination. Operates as a broad incumbent whose specialty expansion can pressure niche CROs.
- Parexel International: Large global CRO providing Phase I-IV services, particularly strong in biotech and specialty therapeutic areas. Represents incumbent competition for both sponsors and talent.
- IQVIA: Largest global full-service CRO and life sciences services platform. Sets pricing benchmarks and increasingly competes in specialty therapeutic areas, representing a structural incumbent threat to LumaBridge.
- Labcorp Drug Development (Fortrea): Large incumbent CRO spun out from Labcorp, providing full-service clinical development across all therapeutic areas. Competes with specialty CROs including LumaBridge on both standalone and full-service bids.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
LumaBridge social profiles
Digital presenceLumaBridge financial estimates
Financial estimateRevenue estimate
Valuation estimate
LumaBridge leadership team
Management profileNumber of profiles
Profiles2 records
LumaBridge funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LumaBridge M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LumaBridge
What does LumaBridge do?
LumaBridge is a specialty clinical research organisation that provides tailored clinical trial guidance and personalised services to sponsor companies. It supports the planning and execution of clinical studies through customised engagement, operating as a boutique CRO rather than a large full-service provider.
When was LumaBridge founded?
LumaBridge was founded in 2014. It employs 51 to 100 people.
Where is LumaBridge based?
LumaBridge is headquartered in San Antonio, United States, in the North America region.
Who are LumaBridge's main competitors?
Direct peers on record are Clinipace Worldwide, Synteract (now part of Citation Bio Group), Worldwide Clinical Trials, Medpace Holdings, CTI Clinical Trial & Consulting Services and Premier Research. Broad incumbents are ICON plc, Parexel International, IQVIA and Labcorp Drug Development (Fortrea).
Does LumaBridge have an API?
No public API is recorded for LumaBridge.
What industry is LumaBridge in?
LumaBridge's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54 and its SIC code is 8731.